Is XRAY a buy or sell right now?

Innellis AI committee rates Dentsply Sirona Buy with a composite score of 68/100.

Do analysts agree on XRAY?

4 AI analysts evaluated Dentsply Sirona, with 75 percent agreement on the overall direction.

What is the near-term upside for XRAY?

Based on nearby resistance levels, Dentsply Sirona has a near-term technical upside of +13.8 percent. This is a support/resistance measure, not a price target.

XRAY · NASDAQ · STOCK

Dentsply Sirona (XRAY) Stock Analysis

Healthcare Updated September 05, 2026

$11.38

52W $9.41 – $14.86

AI Score

68/100

Market Cap

$2.29B

P/E Ratio

-4.2

Beta

0.87

Is XRAY Bullish or Bearish?

Bullish. Innellis AI committee rates Dentsply Sirona (XRAY) Buy with a composite score of 68/100 , based on 4 analysts with 75% agreement. Last updated September 05, 2026.

What Would Change This View

Upgrade to Strong Buy: Requires a committee score of 75.0 — +6.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch: Requires the score to fall below 55.0 — -13.17 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case

Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
MACD histogram positive -- bullish momentum — Technical
Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
News sentiment is positive (+0.38 across 8 articles, 14d) — News

Bear Case

Price structure making lower highs and lower lows — Technical
Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical

Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.

Price History (6M)

AI Investment Committee

Committee Consensus As of September 05, 2026

Overall Committee Score

68/100

Agreement

75%

Analysts

Conviction

High

Sector Rank

Top 3%

of 192 Healthcare peers

Growth Analyst bullish

85 / 100 · Low confidence

Strong, accelerating growth with consistent execution

+ Quarter-over-quarter growth rate is ACCELERATING, not just positive

Technical Analyst neutral

53 / 100 · High confidence

Mixed or range-bound price action

+ MACD histogram positive -- bullish momentum

− Price structure making lower highs and lower lows

Macro Analyst bullish

65 / 100 · Low confidence

Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor

News Analyst bullish

70 / 100 · Low confidence

News flow and recent filings/analyst actions are net positive

+ News sentiment is positive (+0.38 across 8 articles, 14d)

Portfolio Manager neutral

45 / 100 · High confidence

Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position

+ Portfolio position concentration is currently healthy

− Sector concentration is already high (HHI 3059.07)

Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened significantly from 50.8 to 68.2.

Recommendation changed from Watch to Buy.
Conviction strengthened -- analysts aligned more closely.
Committee agreement increased sharply from 33% to 75%.
Bullish support removed: 2 signal(s) disappeared.
New bullish signals: 1 appeared.
Bearish pressure eased: 4 signal(s) disappeared.
Analyst(s) changed stance: Growth Analyst.
Analyst(s) abstained: Risk Analyst, Value Analyst.

Analyst-level changes:

Growth Analyst: stance neutral->bullish; score 50->85 (+35).
News Analyst: +1 bullish signal(s).
Risk Analyst abstained (was bearish at 30).
Value Analyst abstained (was bearish at 40).

Comparing 2026-09-04 to 2026-09-05 (1 day apart).

Technical Analysis

RSI (14)

55.8

Neutral

MACD Histogram

0.045

Bullish Momentum

Trend Direction

Downtrend

Weekly: Downtrend

Market Structure

Hh Hl

Support

$10.86

Resistance

$13.01

Bollinger %B

0.65

Inside Bands

Price vs Moving Averages

EMA 9

$11.17 Above

EMA 21

$11.45 Below

EMA 50

$11.70 Below

EMA 200

$12.20 Below

Fundamental Analysis

Valuation

Growth

Profitability

Financial Health

Cash Flow

Valuation

P/E Ratio -4.2×

P/B Ratio 1.69×

PEG Ratio -0.08

Dividend Yield 2.80%

52W High $14.86

52W Low $9.41

Quality & Growth

ROE -4462.7%

ROA -1101.5%

Gross Margin 4952.0%

Operating Margin 1169.4%

Revenue Growth YoY —

Debt / Equity 1.71

AI Fundamental Assessment

P/E ratio of -4.2 (inexpensive relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -44.6%; Return on assets of -11.0%; Net margin of -15.0%; Gross margin of 49.5%; Current ratio of 1.63 (healthy short-term liquidity); Debt-to-equity of 1.71; Free cash flow per share is positive (0.72); Most recent quarter beat estimates by 46.1%; EPS growth accelerating (+0.0% -> +92.6% QoQ); Average YoY EPS growth of 0.0%; Analyst estimates rising over recent quarters

Get the Full XRAY Analysis

Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A

Open in Terminal →